Lineage Cell Therapeutics (LCTX) Preferred Dividend Payments (2014 - 2015)
Lineage Cell Therapeutics' (LCTX) quarterly Preferred Dividend Payments came in at -$830000.0 in Q4 2015, down 1666.04% year-on-year from $53000.0 in Q4 2014, and down 328.65% quarter-over-quarter from $363000.0 in Q3 2015.
Lineage Cell Therapeutics (LCTX) Preferred Dividend Payments (2014 - 2015) Analysis & Trends
Lineage Cell Therapeutics' Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at -$830000.0 for Q4 2015.
- On a quarterly basis, Preferred Dividend Payments fell 1666.04% year-over-year to -$830000.0 in Q4 2015; TTM through Dec 2016 was -$830000.0, a 129.28% decrease from a year earlier, with the FY2015 full-year figure at -$415000.0, down 577.01% from the prior year.
- Preferred Dividend Payments declined to -$830000.0 in Q4 2015 per LCTX's latest filing, from $363000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $363000.0 in Q3 2015 and bottomed at -$830000.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -830,000.00 |
| Sep 30, 2015 | 363,000.00 |
| Jun 30, 2015 | 52,000.00 |
| Dec 31, 2014 | 53,000.00 |
| Sep 30, 2014 | 34,000.00 |
| Jun 30, 2014 | 34,000.00 |